The Food and Drug Administration has approved a cheaper generic version of the allergy drug EpiPen, which was the subject of intense public scrutiny a few years ago due to its $600 price tag for a two-pack.

The agency said on Thursday that the move was part of an effort to speed up approval of more complex generic products in order to lower prices.